Quality of prostate cancer screening information on the websites of nationally recognized cancer centers and health organizations

Bogdan Alexandru Manole, Daniel V. Wakefield, Austin P. Dove, Caleb R. Dulaney, Samuel R. Marcrom, David Schwartz, Michael R. Farmer

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to survey the accessibility and quality of prostate-specific antigen (PSA) screening information from National Cancer Institute (NCI) cancer center and public health organization Web sites. Methods and materials: We surveyed the December 1, 2016, version of all 63 NCI-designated cancer center public Web sites and 5 major online clearinghouses from allied public/private organizations (cancer.gov, cancer.org, PCF.org, USPSTF.org, and CDC.gov). Web sites were analyzed according to a 50-item list of validated health care information quality measures. Web sites were graded by 2 blinded reviewers. Interrater agreement was confirmed by Cohen kappa coefficient. Results: Ninety percent of Web sites addressed PSA screening. Cancer center sites covered 45% of topics surveyed, whereas organization Web sites addressed 70%. All organizational Web pages addressed the possibility of false-positive screening results; 41% of cancer center Web pages did not. Forty percent of cancer center Web pages also did not discuss next steps if a PSA test was positive. Only 6% of cancer center Web pages were rated by our reviewers as “superior” (eg, addressing >75% of the surveyed topics) versus 20% of organizational Web pages. Interrater agreement between our reviewers was high (kappa coefficient = 0.602). Conclusion: NCI-designated cancer center Web sites publish lower quality public information about PSA screening than sites run by major allied organizations. Nonetheless, information and communication deficiencies were observed across all surveyed sites. In an age of increasing patient consumerism, prospective prostate cancer patients would benefit from improved online PSA screening information from provider and advocacy organizations. Validated cancer patient Web educational standards remain an important, understudied priority.

Original languageEnglish (US)
Pages (from-to)275-278
Number of pages4
JournalPractical Radiation Oncology
Volume8
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Organizations
Health
Prostate-Specific Antigen
Neoplasms
National Cancer Institute (U.S.)
Quality of Health Care
Centers for Disease Control and Prevention (U.S.)
Public Health
Communication

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Quality of prostate cancer screening information on the websites of nationally recognized cancer centers and health organizations. / Manole, Bogdan Alexandru; Wakefield, Daniel V.; Dove, Austin P.; Dulaney, Caleb R.; Marcrom, Samuel R.; Schwartz, David; Farmer, Michael R.

In: Practical Radiation Oncology, Vol. 8, No. 4, 01.07.2018, p. 275-278.

Research output: Contribution to journalArticle

Manole, Bogdan Alexandru ; Wakefield, Daniel V. ; Dove, Austin P. ; Dulaney, Caleb R. ; Marcrom, Samuel R. ; Schwartz, David ; Farmer, Michael R. / Quality of prostate cancer screening information on the websites of nationally recognized cancer centers and health organizations. In: Practical Radiation Oncology. 2018 ; Vol. 8, No. 4. pp. 275-278.
@article{ec3d23e1a26e4b2985f0b8bb0bcf8bbe,
title = "Quality of prostate cancer screening information on the websites of nationally recognized cancer centers and health organizations",
abstract = "Purpose: The purpose of this study was to survey the accessibility and quality of prostate-specific antigen (PSA) screening information from National Cancer Institute (NCI) cancer center and public health organization Web sites. Methods and materials: We surveyed the December 1, 2016, version of all 63 NCI-designated cancer center public Web sites and 5 major online clearinghouses from allied public/private organizations (cancer.gov, cancer.org, PCF.org, USPSTF.org, and CDC.gov). Web sites were analyzed according to a 50-item list of validated health care information quality measures. Web sites were graded by 2 blinded reviewers. Interrater agreement was confirmed by Cohen kappa coefficient. Results: Ninety percent of Web sites addressed PSA screening. Cancer center sites covered 45{\%} of topics surveyed, whereas organization Web sites addressed 70{\%}. All organizational Web pages addressed the possibility of false-positive screening results; 41{\%} of cancer center Web pages did not. Forty percent of cancer center Web pages also did not discuss next steps if a PSA test was positive. Only 6{\%} of cancer center Web pages were rated by our reviewers as “superior” (eg, addressing >75{\%} of the surveyed topics) versus 20{\%} of organizational Web pages. Interrater agreement between our reviewers was high (kappa coefficient = 0.602). Conclusion: NCI-designated cancer center Web sites publish lower quality public information about PSA screening than sites run by major allied organizations. Nonetheless, information and communication deficiencies were observed across all surveyed sites. In an age of increasing patient consumerism, prospective prostate cancer patients would benefit from improved online PSA screening information from provider and advocacy organizations. Validated cancer patient Web educational standards remain an important, understudied priority.",
author = "Manole, {Bogdan Alexandru} and Wakefield, {Daniel V.} and Dove, {Austin P.} and Dulaney, {Caleb R.} and Marcrom, {Samuel R.} and David Schwartz and Farmer, {Michael R.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.prro.2017.12.010",
language = "English (US)",
volume = "8",
pages = "275--278",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Quality of prostate cancer screening information on the websites of nationally recognized cancer centers and health organizations

AU - Manole, Bogdan Alexandru

AU - Wakefield, Daniel V.

AU - Dove, Austin P.

AU - Dulaney, Caleb R.

AU - Marcrom, Samuel R.

AU - Schwartz, David

AU - Farmer, Michael R.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose: The purpose of this study was to survey the accessibility and quality of prostate-specific antigen (PSA) screening information from National Cancer Institute (NCI) cancer center and public health organization Web sites. Methods and materials: We surveyed the December 1, 2016, version of all 63 NCI-designated cancer center public Web sites and 5 major online clearinghouses from allied public/private organizations (cancer.gov, cancer.org, PCF.org, USPSTF.org, and CDC.gov). Web sites were analyzed according to a 50-item list of validated health care information quality measures. Web sites were graded by 2 blinded reviewers. Interrater agreement was confirmed by Cohen kappa coefficient. Results: Ninety percent of Web sites addressed PSA screening. Cancer center sites covered 45% of topics surveyed, whereas organization Web sites addressed 70%. All organizational Web pages addressed the possibility of false-positive screening results; 41% of cancer center Web pages did not. Forty percent of cancer center Web pages also did not discuss next steps if a PSA test was positive. Only 6% of cancer center Web pages were rated by our reviewers as “superior” (eg, addressing >75% of the surveyed topics) versus 20% of organizational Web pages. Interrater agreement between our reviewers was high (kappa coefficient = 0.602). Conclusion: NCI-designated cancer center Web sites publish lower quality public information about PSA screening than sites run by major allied organizations. Nonetheless, information and communication deficiencies were observed across all surveyed sites. In an age of increasing patient consumerism, prospective prostate cancer patients would benefit from improved online PSA screening information from provider and advocacy organizations. Validated cancer patient Web educational standards remain an important, understudied priority.

AB - Purpose: The purpose of this study was to survey the accessibility and quality of prostate-specific antigen (PSA) screening information from National Cancer Institute (NCI) cancer center and public health organization Web sites. Methods and materials: We surveyed the December 1, 2016, version of all 63 NCI-designated cancer center public Web sites and 5 major online clearinghouses from allied public/private organizations (cancer.gov, cancer.org, PCF.org, USPSTF.org, and CDC.gov). Web sites were analyzed according to a 50-item list of validated health care information quality measures. Web sites were graded by 2 blinded reviewers. Interrater agreement was confirmed by Cohen kappa coefficient. Results: Ninety percent of Web sites addressed PSA screening. Cancer center sites covered 45% of topics surveyed, whereas organization Web sites addressed 70%. All organizational Web pages addressed the possibility of false-positive screening results; 41% of cancer center Web pages did not. Forty percent of cancer center Web pages also did not discuss next steps if a PSA test was positive. Only 6% of cancer center Web pages were rated by our reviewers as “superior” (eg, addressing >75% of the surveyed topics) versus 20% of organizational Web pages. Interrater agreement between our reviewers was high (kappa coefficient = 0.602). Conclusion: NCI-designated cancer center Web sites publish lower quality public information about PSA screening than sites run by major allied organizations. Nonetheless, information and communication deficiencies were observed across all surveyed sites. In an age of increasing patient consumerism, prospective prostate cancer patients would benefit from improved online PSA screening information from provider and advocacy organizations. Validated cancer patient Web educational standards remain an important, understudied priority.

UR - http://www.scopus.com/inward/record.url?scp=85041951526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041951526&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2017.12.010

DO - 10.1016/j.prro.2017.12.010

M3 - Article

VL - 8

SP - 275

EP - 278

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 4

ER -